<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04776135</url>
  </required_header>
  <id_info>
    <org_study_id>MT-1186-Z-101</org_study_id>
    <nct_id>NCT04776135</nct_id>
  </id_info>
  <brief_title>Comparative Bioavailability Study of Oral Edaravone Administered Orally and Via a Nasogastric Tube</brief_title>
  <official_title>A Phase I, Randomized, Open-Label, Crossover-Design, Single-Dose Study to Investigate the Safety, Tolerability and Comparative Bioavailability of Oral Edaravone Administered Orally and Via a Nasogastric Tube (NGT) in Healthy Adult Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mitsubishi Tanabe Pharma Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mitsubishi Tanabe Pharma Corporation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To investigate the comparative bioavailability of edaravone oral suspension administered&#xD;
      orally and via a nasogastric tube in healthy adult subjects&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 26, 2021</start_date>
  <completion_date type="Actual">April 16, 2021</completion_date>
  <primary_completion_date type="Actual">April 1, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Plasma concentrations of edaravone</measure>
    <time_frame>Day 1 to 2</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the concentration versus time curve (AUC) of edaravone</measure>
    <time_frame>Day 1 to 2</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum plasma concentration (Cmax) of edaravone</measure>
    <time_frame>Day 1 to 2</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to reach maximum plasma concentration (tmax) of edaravone</measure>
    <time_frame>Day 1 to 2</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Terminal elimination half-life (t1/2) of edaravone</measure>
    <time_frame>Day 1 to 2</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Apparent terminal elimination rate constant (Kel) of edaravone</measure>
    <time_frame>Day 1 to 2</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean residence time (MRT) of edaravone</measure>
    <time_frame>Day 1 to 2</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Apparent total clearance (CL/F) of edaravone</measure>
    <time_frame>Day 1 to 2</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Apparent distribution volume at elimination phase (Vz/F) of edaravone</measure>
    <time_frame>Day 1 to 2</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Apparent distribution volume at steady state (Vss/F) of edaravone</measure>
    <time_frame>Day 1 to 2</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Adverse events and adverse drug reactions</measure>
    <time_frame>The provision of informed consent to Day 11</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">36</enrollment>
  <condition>Healthy Adult Subjects</condition>
  <arm_group>
    <arm_group_label>MT-1186 orally</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects receive the edaravone oral suspension orally.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MT-1186 via a nasogastric tube</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects receive the edaravone oral suspension via a nasogastric tube</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MT-1186</intervention_name>
    <description>Suspension</description>
    <arm_group_label>MT-1186 orally</arm_group_label>
    <arm_group_label>MT-1186 via a nasogastric tube</arm_group_label>
    <other_name>Edaravone</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria: Subjects who meet all of the following criteria and who have the&#xD;
        capability of giving informed consent will be included in the study.&#xD;
&#xD;
          1. Healthy adult male or female volunteers&#xD;
&#xD;
          2. Japanese&#xD;
&#xD;
          3. Subjects aged between 20 and 45 years at the time of informed consent&#xD;
&#xD;
          4. Subjects who have thoroughly understood the contents of the study and voluntarily&#xD;
             provided written informed consent to participate in the study&#xD;
&#xD;
        Exclusion Criteria: Subjects who meet any of the following criteria between screening and&#xD;
        investigational product administration will be excluded from the study.&#xD;
&#xD;
          1. Subjects with a current or previous history of cardiac, hepatic, renal,&#xD;
             gastrointestinal, respiratory, psychiatric/nervous, hematopoietic, or endocrine&#xD;
             diseases, and those whom the investigator (or subinvestigator) deems unsuitable for&#xD;
             the study&#xD;
&#xD;
          2. History of drug or food allergies&#xD;
&#xD;
          3. History of alcohol or drug abuse or dependence&#xD;
&#xD;
          4. Body mass index (BMI) of &lt;18.0 or &gt;30.0, or a body weight of &lt;50 kg (BMI formula: body&#xD;
             weight [kg]/height [m]2, rounded to one decimal place)&#xD;
&#xD;
          5. Positive test for any of the following at screening: Hepatitis B surface antigen,&#xD;
             serological test for syphilis, hepatitis C virus antibody, or human immunodeficiency&#xD;
             virus antigen/antibody, subject has a positive COVID-19 virus test on Day -1&#xD;
&#xD;
          6. Any clinically significant 12-lead ECG abnormality or QTcF interval ≥450 msec&#xD;
&#xD;
          7. Blood donation or sampling with a total volume of ≥400 mL within 12 weeks, ≥200 mL&#xD;
             within 4 weeks, or ≥800 mL within one year before providing informed consent&#xD;
&#xD;
          8. Blood component donation or blood sampling within 2 weeks before providing informed&#xD;
             consent, or blood donation and transfusion from informed consent to the start of&#xD;
             investigational product administration&#xD;
&#xD;
          9. Subjects who have undergone any surgery known to affect the gastrointestinal&#xD;
             absorption of drugs (except for appendectomy and herniotomy)&#xD;
&#xD;
         10. Female subjects of childbearing potential who do not agree to use an effective method&#xD;
             of contraception from screening or 2 weeks before the start of investigational product&#xD;
             administration, whichever comes earlier, to 14 days after the completion (or&#xD;
             discontinuation) of investigational product administration. Male subjects who do not&#xD;
             agree to use an effective method of contraception from the start of investigational&#xD;
             product administration to 14 days after the completion (or discontinuation) of&#xD;
             investigational product administration&#xD;
&#xD;
         11. Subjects who have previously received edaravone&#xD;
&#xD;
         12. Subjects who have participated in another clinical study and received an&#xD;
             investigational product within 12 weeks before providing informed consent&#xD;
&#xD;
         13. Subjects who have used any drugs other than the single use of acetylsalicylic acid&#xD;
             within 7 days before the initiation of investigational product administration&#xD;
&#xD;
         14. Use of alcohol or any products containing xanthin or caffeine within 24 hours before&#xD;
             screening and visit on Day -1&#xD;
&#xD;
         15. Use of any nutritional supplement(s) within 7 days before the initiation of&#xD;
             investigational product administration&#xD;
&#xD;
         16. Use of grapefruit, grapefruit juice, or any processed food(s) containing these&#xD;
             substances within 24 hours before screening and visit on Day -1&#xD;
&#xD;
         17. Use of any tobacco or nicotine-containing product(s) within 24 hours before screening&#xD;
             and visit on Day -1&#xD;
&#xD;
         18. Female subjects who have a positive pregnancy test at screening and on Day -1, are&#xD;
             pregnant or breast feeding, or plan to get pregnant during the study&#xD;
&#xD;
         19. Subjects with a history of reconstructive nasal surgery, or any evidence of&#xD;
             deformities or asymmetry of the nose, non-patent nares/obstructed nasal airway, or the&#xD;
             presence of nasal ulcers or polyps that would prevent an adequate NGT insertion.&#xD;
&#xD;
         20. Subjects judged by the investigator (or subinvestigator) to be unsuitable for the&#xD;
             study for any other reason&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>General Manager</last_name>
    <role>Study Director</role>
    <affiliation>Mitsubishi Tanabe Pharma Corporation</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Investigational site</name>
      <address>
        <city>Tokyo</city>
        <state>Toshima-ku</state>
        <zip>171-0014</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>February 25, 2021</study_first_submitted>
  <study_first_submitted_qc>February 25, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 1, 2021</study_first_posted>
  <last_update_submitted>May 12, 2021</last_update_submitted>
  <last_update_submitted_qc>May 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Edaravone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

